Biomarkers of Disease: An Evidence-Based Approach

Biomarkers of Disease: An Evidence-Based Approach

by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston
     
 

ISBN-10: 0521088607

ISBN-13: 9780521088602

Pub. Date: 10/30/2008

Publisher: Cambridge University Press

This new publication takes a critical, evidence-based look at the efficacy of new diagnostic tests which are increasingly being used to evaluate organ damage and dysfunction. The use of biomarkers is growing, with a steady stream of new products being brought out by the pharmaceutical industry. However, in many cases the evidence which supports the use of these new…  See more details below

Overview

This new publication takes a critical, evidence-based look at the efficacy of new diagnostic tests which are increasingly being used to evaluate organ damage and dysfunction. The use of biomarkers is growing, with a steady stream of new products being brought out by the pharmaceutical industry. However, in many cases the evidence which supports the use of these new methods as opposed to traditional biochemical tests has not yet been demonstrated, and it is intended that this volume will help clarify the strengths and weaknesses of using these biomarkers across a wide range of applications and in the various organs of the body. This approach will provide an invaluable overview of the diverse applications of biomarkers in medicine.

Product Details

ISBN-13:
9780521088602
Publisher:
Cambridge University Press
Publication date:
10/30/2008
Edition description:
Reprint
Pages:
520
Product dimensions:
6.60(w) x 9.50(h) x 1.20(d)

Table of Contents

List of contributors
Preface
Pt. 1Assessing and utilizing the diagnostic or prognostic power of biomarkers
1Evidence-based medicine: evaluation of biomarkers3
2Development of biomarkers: the industrial perspective16
3Statistical approaches to rational biomarker selection24
4Using intelligent systems in clinical decision support32
Pt. 2Biomarkers of kidney disease and dysfunction
5Biomarkers in renal disease45
6The genetics of renal disease56
7Early markers of nephrotoxicity for environmental and occupational monitoring66
8The early detection of renal impairment in diabetes mellitus. The case for microalbuminuria and other biomarkers76
Pt. 3Biomarkers of bone disease and dysfunction
9Bone turnover markers in clinical practice99
10Biomarkers of bone formation115
11Biochemical markers of bone resorption122
12The clinical application of biomarkers in osteoporosis133
13Sources of preanalytical variability in the measurement of biochemical markers of bone turnover140
14Genetic approaches to the study of complex diseases: osteoporosis159
Pt. 4Biomarkers of liver disease and dysfunction
15Biomarkers of hepatic disease167
16The immunogenetics of metabolic liver disease177
17Toxicogenetic markers of liver dysfunction190
18Prognosis and management of patients with acute liver failure199
19Biomarkers in artificial and bioartificial liver support211
20Prognostic markers in liver disease221
21Apoptosis: biomarkers and the key role of mitochondria228
22Liver regeneration: mechanisms and markers239
23Determinants of responses to viruses and self in liver disease244
24IL-6-type cytokines and signalling in inflammation256
Pt. 5Biomarkers of gastrointestinal disease and dysfunction
25Biomarkers in gastrointestinal disease265
26Tumour markers in gastrointestinal disease272
27Markers of malabsorption: coeliac disease281
Pt. 6Biomarkers in toxicology
28Genomics and biomarkers in toxicology291
29Protein profiling and proteomic databases299
30Biomarkers for evaluating the safety of genetically modified foods313
Pt. 7Biomarkers of cardiovascular disease and dysfunction
31The impact of biochemical tests on patient management325
32Cardiac natriuretic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure334
33Serum markers of inflammation and cardiovascular risk345
34The clinical significance of markers of coagulation in acute coronary syndromes355
35Endothelin: what does it tell us about myocardial and endothelial dysfunction?365
36Homocysteine: a reversible risk factor for coronary heart disease374
37Matrix metalloproteinases and their tissue inhibitors379
Pt. 8Biomarkers of neurological disease and dysfunction
38Biomarkers of neurodegenerative disorders391
39Traumatic brain injury: assessment by biochemical serum markers398
40An overview of S-100[beta] as a clinically useful biomarker of brain tissue damage406
Pt. 9Biomarkers in transplantation
41Monitoring heart and lung transplant patients415
42Monitoring liver transplant recipients423
43Chronic allograft damage index as a surrogate marker for chronic allograft rejection433
44Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy442
45The use of biomarkers for monitoring the response to immunosuppressive drug therapy451
46Post-transplantation bone disease461
47Molecular diagnosis of cytomegalovirus disease467
48Diagnosis and monitoring of inflammatory events in transplant recipients474
Index483

Read More

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >